 |
Dott. M. M. Ciammaichella
Dirigente Medico
Responsabile UAS “Trombosi Venosa Profonda ed Embolia Polmonare”
Responsabile CDF BLSD IRC “Emersan Lateranum”
SC Medicina Interna I° per l'Urgenza
(Direttore: Dott. G. Cerqua)
THORACIC OUTLET SYNDROME
KEY-WORDS: Thoracic outlet syndrome
.
INTRODUCTION
CLINICAL
WORKUP
TREATMENT
MEDICATION
FOLLOW-UP
BIBLIOGRAPHY
.
INTRODUCTION
Background: Thoracic outlet syndrome refers to compression of the neurovascular structures at the superior aperture of the thorax. It represents a constellation of symptoms. The cause, diagnosis and treatment are controversial. The brachial plexus (95%), subclavian vein (4%) and subclavian artery (1%) are effected. Most presentations to the emergency department are nonemergent and require only symptomatic treatment and referral.
Frequency:
- In the U.S. : The overall incidence remains controversial, with reports ranging from 3/1000 to 80/1000 people.
Sex: The sex ratio varies depending on the type of thoracic outlet syndrome (e.g., neurologic, venous or arterial). Overall, the entity is approximately 3 times more common in women.
- Neurologic: The female to male ratio is about 3.5:1.
- Venous: More common in males
- Arterial: No sexual predilection
Age: The onset of symptoms usually occurs between the ages of 20 and 50 years.
CLINICALPATHOPHYSIOLOGY
History:
- Neurological symptoms occur in 95% of cases. The lower 2 nerve roots, C8 and T1, are most commonly (90%) involved, producing pain and paresthesias in the ulnar nerve distribution.
- The second most common anatomic pattern involves the upper 3 nerve roots of the brachial plexus, C5, C6 and C7, with symptoms referred to the neck, ear, upper chest, upper back and outer arm in the radial nerve distribution.
- Pain, particularly in the medial aspect of the arm, forearm and the ring and small digits
- Paresthesias, often nocturnal, awakening patient with pain or numbness
Physical: In the majority of cases, the physical examination is completely normal.
- Provocative tests, such as the Adson, costoclavicular and hyperabduction maneuvers are unreliable. Approximately 92% of asymptomatic patients have variation in the strength of the radial pulse during positional changes.
- The EAST (elevated arm stress test) is of debatable use, but may be the most reliable screening test. It evaluates all 3 types of thoracic outlet syndrome.
- To perform this test, the patient sits with the arms abducted 90 degrees from the thorax and the elbows flexed 90 degrees. The patient then opens and closes the hands for 3 minutes.
- Patients with thoracic outlet syndrome cannot continue this for 3 minutes because of reproduction of symptoms. Patients with carpal tunnel syndrome experience dysesthesias in the fingers, but do not have shoulder or arm pain.
- A positive EAST test and the presence of a radial pulse are strong indicators of neurologic involvement of the brachial plexus.
- Supraclavicular tenderness
- Usually no evidence of muscle atrophy
- Weakness (usually subtle) of affected limb
- Distended superficial veins of the shoulder and chest
- Coolness on the affected side
- Lower blood pressure in affected arm (a reliable indicator of arterial involvement)
- Multiple small infarcts on hand and fingers (embolization)
Causes: There are 3 major causes: anatomic, trauma/repetitive activities and neurovascular entrapment at the costoclavicular space.
- Scalene triangle: Anterior scalene muscle frontally, middle scalene muscle posteriorly and the upper border of first rib inferiorly accounts for the majority of neurologic and arterial thoracic outlet syndromes.
- Cervical ribs are found in the majority of arterial cases but rarely in venous and neurologic cases.
- Congenital fibromuscular bands (up to 80% of patients with neurologic thoracic outlet syndrome)
- Elongated transverse process of C7
- Trauma or Repetitive Activities:
- Motor vehicle accident hyperextension injury, with subsequent fibrosis and scarring
- Effort vein thrombosis (i.e. spontaneous thrombosis of the axillary veins following vigorous arm exertion)
- Musicians can be particularly susceptible owing to their need to maintain the shoulder in abduction or extension for long periods.
- Costoclavicular space: Between the first rib and the head of the clavicle

WORKUP
Lab Studies:
- With the rare exception of a vascular cause, the vast majority of ED presentations will not be emergent. Screening tests may be appropriate if indicated and to rule out other causes. Once the clinical diagnosis is made, most of the imaging studies and other tests should be reserved for the outpatient setting.
Imaging Studies:
- Cervical radiography may demonstrate a skeletal abnormality.
- Color flow duplex scanning for suspected vascular thoracic outlet syndrome
- Arteriogram (indications):
- Evidence of peripheral emboli in the upper extremity
- Suspected subclavian stenosis or aneurysm (e.g., bruit or abnormal supraclavicular pulsation)
- Blood pressure differential greater than 20 mm Hg
- Obliteration of radial pulse during EAST test (elevated arm stress test)
- Venography (indications):
- Persistent or intermittent edema of the hand or arm
- Peripheral unilateral cyanosis
- Prominent venous pattern over the arm, shoulder or chest
- The following special studies are generally appropriate in the outpatient setting. They should be arranged by the primary care physician once the patient has been discharged from the emergency department.
- Nerve conduction evaluation via root stimulation and F wave is the best direct approach to evaluation of neurologic thoracic outlet syndrome.
- Electromyography (EMG) is unreliable and does not provide objective evidence of thoracic outlet syndrome.
- Cervical myelogram, CT or MRI for patients suspected of having cervical disk disease or spinal cord disease
TREATMENT
Emergency Department Care: Most presentations to the emergency department are nonemergent and will require only symptomatic treatment and referral. Vascular thoracic outlet syndrome, although much less common, requires more urgent care.
- Vascular (arterial and venous):
- Vascular surgery consultation
- Color flow duplex scanning
- Angiography or venography
- Neurologic: Conservative outpatient physiotherapy
Consultations:
- Neurologic, orthopedic or vascular surgery consultation(s) may be indicated depending on the type of pathologic condition.
- Physical medicine and rehabilitation physicians are needed for outpatient work up.
.
MEDICATION
In patients with evidence of arterial or venous involvement (ischemia or thrombosis), immediate heparinization is indicated.
Drug Category: Anticoagulants - Prevent recurrent or ongoing thromboembolic occlusion of the vertebrobasilar circulation.
Drug Name |
Heparin - It augments the activity of antithrombin III and prevents the conversion of fibrinogen to fibrin. It does not actively lyse but is able to inhibit further thrombogenesis. It prevents the reaccumulation of a clot after a spontaneous fibrinolysis. |
Adult Dose |
Loading dose: Administer 80 u/kg
Maintenance infusion: Administer 18 u/kg/h
Alternatively, start with 50 u/kg/h, followed by a continuous infusion of 15-25 u/kg/h and increase the dose by 5 u/kg/h q4h prn using PTT results. |
Pediatric Dose |
Loading dose: Administer 50 u/kg/h
Maintenance infusion: Administer 15-25 u/kg/h
Increase the dose by 2-4 u/kg/h q6-8h prn using PTT results. |
Contraindications |
Avoid use in patients with documented hypersensitivity to heparin or related products and those diagnosed with subacute bacterial endocarditis and active bleeding or have a history of heparin-induced thrombocytopenia. |
Interactions |
Digoxin, nicotine, tetracycline, and antihistamines may decrease the effects of this drug. Conversely, NSAIDs, ASA, dextran, dipyridamole, and hydroxychloroquine may increase heparin toxicity. |
Pregnancy |
C - Safety for use during pregnancy has not been established. |
Precautions |
Some preparations contain benzyl alcohol as a preservative and when used in large amounts, it may be associated with fetal toxicity (gasping syndrome). The use of preservative-free heparin is recommended in neonates. Use with caution in patients diagnosed with shock or severe hypotension. |
Drug Name |
Warfarin - It interferes with the hepatic synthesis of vitamin K-dependent coagulation factors. It is used for the prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders.
Tailor the dose to maintain an INR in the range of 2 to 3. |
Adult Dose |
Administer 5-15 mg/d PO qd for 2-5 d and adjust the dose according to the desired INR |
Pediatric Dose |
Administer a weight-based dose of 0.05-0.34 mg/kg/d and adjust the dose according to the desired INR.
Infants may require doses at, or near, the high end of this range. |
Contraindications |
Avoid use in patients with documented hypersensitivity to warfarin or related products, severe liver or kidney disease and open wounds or GI ulcers. |
Interactions |
Many medications may impact warfarin activity. Drugs that may decrease anticoagulant effects include griseofulvin, carbamazepine, glutethimide, estrogens, nafcillin, phenytoin, rifampin, barbiturates, cholestyramine, colestipol, vitamin K, spironolactone, oral contraceptives, and sucralfate.
Some of the medications that may increase the anticoagulant effects of warfarin include oral antibiotics, phenylbutazone, salicylates, sulfonamides, chloral hydrate, clofibrate, diazoxide, anabolic steroids, ketoconazole, ethacrynic acid, miconazole, nalidixic acid, sulfonylureas, allopurinol, chloramphenicol, cimetidine, disulfiram, metronidazole, phenylbutazone, phenytoin, propoxyphene, sulfonamides, gemfibrozil, acetaminophen, and sulindac. |
Pregnancy |
D - Unsafe in pregnancy |
Precautions |
Do not switch brands after achieving a therapeutic response.
Use with caution in patients with active tuberculosis or diabetes.
Patients with protein C or S deficiency are also at risk of developing skin necrosis. |
Drug Category: Thrombolytic - Are use for the vascular thoracic outlet syndrome. The main objective is to restore circulation through a previously occluded vessel by the rapid and complete removal of a pathologic intraluminal thrombus or embolus that has not been dissolved by the endogenous fibrinolytic system.
Drug Name |
Urokinase - It is a direct plasminogen activator that acts on the endogenous fibrinolytic system and converts plasminogen to the enzyme plasmin which in turn degrades fibrin clots, fibrinogen and other plasma proteins. |
Adult Dose |
Loading dose: Administer 4400 u/kg over 10 min and increase to 6000 u/kg/h
Maintenance dose: Administer 1000-6000 u/kg/h |
Pediatric Dose |
Use the same regimen as in adults. |
Contraindications |
Avoid use in patients with documented hypersensitivity to this medication or related products and those with internal bleeding, recent trauma, a history of intracranial or intraspinal surgery or trauma, cerebrovascular accident, and intracranial neoplasm. |
Interactions |
Thrombolytic enzymes, administered alone or in combination with anticoagulants and antiplatelets, may increase the risk of bleeding complications. |
Pregnancy |
B - Usually safe but benefits must outweigh the risks. |
Precautions |
Use with caution in patients receiving intamuscular administration of medications, patients with severe hypertension, and patients that had trauma or surgery in the previous 10 days.
To avoid dislodging a possible deep vein thrombi, do not measure the blood pressure in the lower extremities. Monitor therapy by performing the PT, aPTT, TT or fibrinogen approximately 4 hours after the initiation of therapy.
Monitor therapy by performing the PT, aPTT, TT or fibrinogen approximately 4 hours after the initiation of therapy. |
Drug Category: Tricyclic Anti-Depressants (TCAs) - If analgesic treatment is ineffective, a short, monitored course of tricyclic anti-depressants can be helpful if the time course and symptoms suggest a protracted pain syndrome. The primary care physician or neurologist (not the ED physician)should be the one to prescribe such therapy.
Drug Name |
Doxepin - It inhibits histamine and acetylcholine activity and has been proven useful in the treatment of various forms of depression associated with chronic and neuropathic pain. |
Adult Dose |
Administer 30-150 mg/d hs or in 2-3 divided doses
Gradually increase the dose to 300 mg/d prn |
Pediatric Dose |
Older than 12 years of age: Administer 25-50 mg/d hs or bid-tid and increase gradually to 100 mg/d
It is not recommended for use in children younger than 12 years of age. |
Contraindications |
Avoid use in patients with documented hypersensitivity to this drug or related products, and those with anuria. Also avoid during the acute recovery phase following myocardial infarction and in patients diagnosed with glaucoma. |
Interactions |
TCAs may enhance the effects of anticholinergic medications.
Barbiturates may lower the serum levels of TCAs
Charcoal can prevent TCA absorption, thereby reducing their effectiveness or toxicity.
Cimetidine can increase TCA levels in patients taking cimetidine. Ranitidine may be an alternative.
It can increase blood pressure to dangerous levels and can cause a hypertensive crisis in patients receiving concurrent TCAs. Avoid their coadministration.
TCAs may increase the half-life or bioavailability of dicumarol, possibly resulting in increased anticoagulation effects.
Haloperidol may increase serum concentrations of TCAs.
Levodopa absorption may be delayed and its bioavailability decreased by TCAs. Hypertensive episodes have also occurred.
MAOIs should not be given with or immediately following TCAs as they can produce seizures, sweating, coma, tachycardia, tachypnea, headache, mydriasis, hyperexcitability, hyperthermia, flushing, confusion, hypotension, disseminated intravascular coagulation,and death. At least 7 to 10 days should pass between MAOI discontinuation and TCA institution.
Oral contraceptives inhibit the hepatic metabolism of TCAs and may increase their plasma levels.
Disulfiram and TCA coadministration may result in acute organic brain syndrome. The bioavailability of the antidepressant may also be increased.
TCAs may antagonize guanethidine's antihypertensive action by inhibiting uptake into adrenergic neurons. Avoid this combination when possible.
Phenothiazines may increase serum TCA levels by inhibiting hepatic metabolism.
Smoking may increase the metabolic biotransformation of TCAs. |
Pregnancy |
C - Safety for use during pregnancy has not been established. |
Precautions |
Perform baseline and periodic leukocyte and differential counts and liver function tests. Discontinue the therapy if there is evidence of neutropenia.
Prior to initiation of large doses of TCAs and at appropriate intervals thereafter should monitor ECG. Patients with cardiovascular disease should be monitored.
Elderly patients and patients with cardiac disease or a history of cardiac disease can develop cardiac abnormalities with TCAs.
TCAs may increase the hazards of electroconvulsive therapy. |
Drug Category: Analgesics - Pain control is essential to quality patient care. It ensures patient comfort, promotes pulmonary toilet, and enables physical therapy regimens. Many analgesics have sedating properties which are beneficial for patients that have sustained injuries.
Drug Name |
Acetaminophen - It is the DOC for the treatment of pain in patients with documented hypersensitivity to aspirin, NSAIDs, diagnosed with upper GI disease or are taking oral anticoagulants. |
Adult Dose |
Administer 325-650 mg q4-6h or 1,000 mg tid-qid
Do not exceed 4 g/d
Alternatively, administer 1,000 mg tid or qid up to a maximum of 4 g/d |
Pediatric Dose |
Older than 12 years of age: Administer 325-650 mg q4h
Do not exceed 5 doses in 24 h
Younger than 12 years of age: Administer 10-15 mg/kg/dose q4-6h prn
Do not exceed 2.6 g/d |
Contraindications |
Avoid use in patients with documented hypersensitivity to acetaminophen and with known G-6-P deficiency. |
Interactions |
Rifampin can interact to reduce the analgesic effects of APAP. Conversely, barbiturates, carbamazepine, hydantoins, and isoniazid, may increase APAP hepatotoxicity. |
Pregnancy |
B - Usually safe but benefits must outweigh the risks. |
Precautions |
Hepatotoxicity can occur in chronic alcoholics following various dose levels of acetaminophen. |
Drug Name |
Acetaminophen and codeine - It is a drug combination indicated for the treatment of mild to moderate pain. |
Adult Dose |
Administer 30-60 mg/dose based on codeine content q4-6h or 1-2 tabs q4h
Do not exceed 12 tabs/24 h |
Pediatric Dose |
The recommended dose, based on codeine is 0.5-1 mg/kg/dose. Based on acetaminophen, the recommended dose is 10-15 mg/kg/dose q4h
Do not exceed 2.6 g/24h of acetaminophen |
Contraindications |
Avoid use in patients with documented hypersensitivity to acetaminophen or codeine phosphate. |
Interactions |
The toxicity of this drug increases when administered concurrently with CNS depressants or tricyclic antidepressants. |
Pregnancy |
C - Safety for use during pregnancy has not been established. |
Precautions |
Administer with caution in patients dependent on opiates since this substitution may result in acute opiate withdrawal symptoms. Exercise caution when patients have severe renal or hepatic dysfunction. |
Drug Name |
Ibuprofen - It is usually the DOC for the treatment of mild to moderate pain, if there are no contraindications. |
Adult Dose |
Administer 200-400 mg q4-6h PO while symptoms persist
Do not exceed 3.2 g/d |
Pediatric Dose |
Children 6 months - 12 years of age: Administer 30-70 mg/kg/d divided tid or qid
Start at the lower end of the dosing range and titrate upward to a maximum of 2.4 g/d
Older than 12 years of age: Use the same regimen as in adults |
Contraindications |
Avoid use in patients with documented hypersensitivity to ibuprofen. Because of potential cross-sensitivity to other NSAIDs, do not give these agents to patients whom aspirin, iodides or other NSAIDs induce hypersensitivity.
Do not administer to patients diagnosed with peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, and those at high risk of bleeding. |
Interactions |
Probenecid may increase the concentrations and possibly the toxicity of NSAIDs. Ibuprofen may decrease the effect of loop diuretics when administered concurrently.
Prothrombin time (PT) may increase when ibuprofen is administered concurrently with anticoagulants. Instruct patients to watch for signs and symptoms of bleeding.
Ibuprofen and other NSAIDs may increase serum lithium levels and the risk of methotrexate toxicity. |
Pregnancy |
B - Usually safe but benefits must outweigh the risks. |
Precautions |
Exercise caution in patients with congestive heart failure, hypertension, and decreased renal and hepatic function. |
.
FOLLOW-UP
Further Inpatient Care:
- Angiography or venography
- Color flow duplex scanning
- Catheter-directed local infusion of thrombolytic agent
- Thrombectomy (for total thrombotic obstruction)
- Fogarty catheter embolectomy
- Emergent or urgent surgical exploration
- Neurologic (Operative therapy for failed conservative approach - more than 4 months): Supraclavicular decompression (anterior and middle scalenectomy, excision of a cervical rib if present and, occasionally, first rib resection)
Further Outpatient Care:
- Stress avoidance, work simplification and job site modification to avoid sustained contraction and repetitive or overhead work that exacerbates symptoms
- Address myofascial or chronic pain elements through exercise programs, good posture and self-management.
- Maximize the potential outlet space through a program of stretching and strengthening of the shoulder-elevating mechanism.
- Trapezius and rhomboid strengthening (e.g., shoulder shrugs and bilateral shoulder retraction while standing or lying prone)
- Shoulder mobilization (e.g., hand circles and standing corner pushups)
- Postural exercises (e.g., cervical and lumbar spine extension)
In/Out Patient Meds:
- Coumadin: Anticoagulate for a minimum of 3 months for vascular thoracic outlet syndrome
- Analgesics are seldom helpful except to assist in the institution of a progressive exercise program.
- Tricyclic Antidepressants: A short-monitored course may be helpful if the time course and symptoms suggest a protracted pain syndrome.
Transfer:
- Vascular: For definitive diagnosis and treatment if unavailable at current institution
Complications:
- Poststenotic aneurysm formation
Prognosis:
- Neurologic thoracic outlet syndrome is generally neither progressive nor likely to resolve spontaneously.
- Arterial and venous thoracic outlet syndrome usually results in a good outcome with adequate treatment.

BIBLIOGRAPHY
- Aufderheide TP : Peripheral arteriovascular disease. Emergency Medicine: Concepts and Clinical Practice 1998; 2: 1844-1847.
- Hood DB, Kuehne J, Yellin AE: Vascular complications of thoracic outlet syndrome. Am Surg 1997 Oct; 63(10): 913-7.
- Oates SD , Daley RA: Thoracic outlet syndrome. Hand Clin 1996 Nov; PT - REVIEW LITERATURE(4): 705-18.
- Plewa MC, Delinger M: The false-positive rate of thoracic outlet syndrome shoulder maneuvers in healthy subjects. Acad Emerg Med 1998 Apr; 5(4): 337-42.
- Weber RJ, Lebduskin S: Rehabilitation issues in plexopathies. Physical Medicine and Rehabilitation 1988; 996-998.
|